The problem of legalized use of fly agarics and diagnosis based on the results of clinical laboratory diagnostics (literature review)

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In recent years, the popularity of fly agaric «microdosing» has increased, which involves their systematic use in small doses (usually several grams) in order to provide a "therapeutic effect without harm to the body." The market offers capsules, dried caps of red fly agaric (Amanita muscaria) and pantherine fly agaric (Amanita pantherina), which until recently were actively sold by individual entrepreneurs on Russian e-commerce platforms. At the federal level, the storage, purchase and sale of pantherine and red fly agarics, as well as psychoactive compounds in their composition, such as ibotenic acid and muscimol, are not regulated in the Russian Federation, which has led to their recreational use and, as a result, a large number of poisonings.

The purpose of the work is to review the literature on the main manifestations and features of the action of toxicants of the red and panther fly agarics during recreational use by humans, motives for use, statistics of poisoning, toxicodynamics and toxicokinetics of fly agaric alkaloids and the chemical composition of the species.

As a result of a consistent analysis of available literature data, the chemical composition of the red fly agaric (Amanita muscaria) and the panther fly agaric (Amanita pantherina) was examined, explaining the reason for the recreational use of raw materials (dried caps and capsules). The psychoactive components of the fly agaric are ibotenic acid, muscimol and methyltetrahydrocarbolinecarboxylic acid, which have an exciting, inhibitory and hallucinogenic effect on the central nervous system. The literature does not contain data on the methods for detecting the most important chemical components of the red fly agaric and panther fly agaric responsible for the psychotropic effect, which is an urgent problem of clinical laboratory diagnostics.

全文:

受限制的访问

作者简介

Е. Evdokimova

St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation; Scientific and Clinical Center of Toxicology named after Academician S.N. Golikov of the Federal Medical and Biological Agency

编辑信件的主要联系方式.
Email: innova.2000@mail.ru
ORCID iD: 0009-0001-6759-526X
SPIN 代码: 4063-1760

Junior Research Scientist

俄罗斯联邦, str. Professora Popova, 14, lit. A, municipal district Aptekarsky Island, St. Petersburg, 197022; Bekhtereva str. 1, St. Petersburg, 192019

О. Balabanova

St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation; St. Petersburg Research Institute of Emergency Medicine named after. I.I. Dzhanelidze

Email: innova.2000@mail.ru
ORCID iD: 0000-0002-8636-9858
SPIN 代码: 6286-3797

Ph.D. (Med.), Lecturer at the Department of Pharmaceutical Chemistry

俄罗斯联邦, str. Professora Popova, 14, lit. A, municipal district Aptekarsky Island, St. Petersburg, 197022; Budapestskaya str., 3, lit. A, St. Petersburg, 192242

D. Pshennikova

St. Petersburg Research Institute of Emergency Medicine named after. I.I. Dzhanelidze

Email: olga.strelova@pharminnotech.com
ORCID iD: 0009-0004-2531-410X
SPIN 代码: 3810-1510

Clinical Laboratory Diagnostics Doctor

俄罗斯联邦, Budapestskaya str., 3, lit. A, St. Petersburg, 192242

Е. Kuznetsova

Scientific and Clinical Center of Toxicology named after Academician S.N. Golikov of the Federal Medical and Biological Agency

Email: olga.strelova@pharminnotech.com
ORCID iD: 0009-0008-7670-553X

Junior Research Scientist

俄罗斯联邦, Bekhtereva str. 1, St. Petersburg, 192019

O. Strelova

St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation

Email: olga.strelova@pharminnotech.com
ORCID iD: 0000-0001-6737-1023
SPIN 代码: 1519-7618

Dr.Sc. (Pharm.), Professor, Head of the Department of Pharmaceutical Chemistry

俄罗斯联邦, str. Professora Popova, 14, lit. A, municipal district Aptekarsky Island, St. Petersburg, 197022

参考

  1. Flament E., Guitton J., Gaulier J. M. et al. Human Poisoning from Poisonous Higher Fungi: Focus on Analytical Toxicology and Case Reports in Forensic Toxicology. Pharmaceuticals (Basel). 2020; 13(12): 454. doi: 10.3390/ph13120454.
  2. Meisel E.M., Morgan B., Schwartz M. et al. Two Cases of Severe Amanita Muscaria Poisoning Including a Fatality. Wilderness Environ Med. 2022; 33(4): 412–416. doi: 10.1016/j.wem.2022.06.002.
  3. Chilton W.S., Ott J. Toxic metabolites of Amanita pantherina, A. cothurnata, A. muscaria and other Amanita species. Lloydia. 1976; 39(2-3): 150–157.
  4. Okhovat A., Cruces W., Docampo-Palacios M. et al Psychoactive Isoxazoles, Muscimol, and Isoxazole Derivatives from the Amanita (Agaricomycetes) Species: Review of New Trends in Synthesis, Dosage, and Biological Properties. Int J Med Mushrooms. 2023; 25(9): 1–10. doi: 10.1615/IntJMed-Mushrooms.2023049458.
  5. Patočka, J., Kocandrlová B. Pharmacologically and toxicologically relevant components of Amanita muscaria. Mil. Med. Sci. Lett. 2017; 86: 122–134. doi: 10.31482/mmsl.2017.020.
  6. Lee M. R., Dukan E., Milne I. Amanita muscaria (fly agaric): from a shamanistic hallucinogen to the search for acetylcholine. J R Coll Physicians Edinb. 2018; 48(1): 85–91. doi: 10.4997/JRCPE.2018.119.
  7. Deja S., Wieczorek P. P., Halama M. et al. Do differences in chemical composition of stem and cap of Amanita muscaria fruiting bodies correlate with topsoil type? PLoS One. 2014; 9(12): 84–104. doi: 10.1371/journal.pone.0104084.
  8. Kosentka P., Sprague S.L., Ryberg M. et al. Evolution of the toxins muscarine and psilocybin in a family of mushroomforming fungi. PLoS One. 2013; 8(5): 64–646. doi: 10.1371/journal.pone.0064646.
  9. White J., Weinstein S.A., De Haro L. et al. Mushroom poisoning: A proposed new clinical classification. Toxicon. 2019; 157: 53–65. doi: 10.1016/j.toxicon.2018.11.007.
  10. Krejcí A., Michal P., Jakubík J. et al Regulation of signal transduction at M2 muscarinic receptor. Physiol Res. 2004; 53(Suppl) 1: 131–140.
  11. Сафронова Е.С., Волков С.А. Холинергические лекарственные средства. М-холиномиметики (часть 1). Медицинские науки: вопросы теории и практики, сборник статей Международной научно-практической конференции. Пенза: МЦНС «Наука и Просвещение» 2020:44. [Safronova E.S., Volkov S.A. Kholinergicheskie lekarstvennye sredstva. M-kholinomimetiki (chast' 1). Meditsinskie nauki: voprosy teorii i praktiki, sbornik statei Mezhdunarodnoi nauchno-prakticheskoi konferentsii. Penza: MTSNS «Nauka i Prosveshchenie». 2020; 44. (In Russ.).].
  12. Ковязина И.В., Хамидуллина А.А. Мускариновые холино-рецепторы в скелетной мышце: локализация и функциональная роль. Acta Naturae. 2023; 15(4): 44–55. [Kovyazina I.V., Khamidullina A.A. Muskarinovye kholinoretseptory v skeletnoi myshtse: lokalizatsiya i funktsional'naya rol'. Acta Naturae. 2023; 15(4): 44–55. (In Russ.)]. doi: 10.32607/actanaturae.25259.
  13. Moran S.P., Maksymetz J., Conn P.J. Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders. Trends Pharmacol Sci. 2019; 40(12): 1006–1020. doi: 10.1016/j.tips.2019.10.007.
  14. Медицинская токсикология: национальное руководство. Под ред. Е.А. Лужникова. М.: Геотар-Медиа. 2012: 923. [Meditsinskaya toksikologiya: natsional'noe rukovodstvo. Pod red. E.A. Luzhnikova. M.: Geotar-Media. 2012: 923. (In Russ.)].
  15. Stebelska K. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Ther Drug Monit. 2013; 35(4): 420–442. doi: 10.1097/FTD.0b013e31828741a5.
  16. Michelot D., Melendez-Howell L.M. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. 2003; 107(Pt 2): 131–146. doi: 10.1017/s0953756203007305.
  17. Kim E.J., Kwon O.S., Hur C.G. et al. Muscimol Directly Activates the TREK-2 Channel Expressed in GABAergic Neurons through Its N-Terminus. Int J Mol Sci. 2021; 22(17): 9320. doi: 10.3390/ijms22179320.
  18. Zhu S., Noviello C.M., Teng J. et al. Structure of a human synaptic GABAA receptor. Nature. 2018; 559(7712): 67–72. doi: 10.1038/s41586-018-0255-3.
  19. Leas E.C., Satybaldiyeva N., Kepner W. et al. Need for a Public Health Response to the Unregulated Sales of Amanita muscaria Mushrooms. Am J Prev Med. 2024; May 31. doi: 10.1016/j.amepre.2024.05.006.
  20. Krogsgaard-Larsen P., Hansen J.J. Naturally-occurring excitatory amino acids as neurotoxins and leads in drug design. Toxicol Lett. 1992; 64–65 Spec No: 409–416. doi: 10.1016/0378-4274(92)90214-5.
  21. Гордеева О.В. Психологические эффекты мухомора красного (Amanita muscaria). Сибирские исторические исследования. 2017; 78(2): 152–183. [Gordeeva O.V. Psikhologicheskie ehffekty mukhomora krasnogo (Amanita muscaria). Sibirskie istoricheskie issledovaniya. 2017; 78(2): 152–183. (In Russ.)]. doi: 10.17223/2312461X/16/9.
  22. Vendramin A., Brvar M. Amanita muscaria and Amanita pantherina poisoning: two syndromes. Toxicon. 2014; 90: 269–272. doi: 10.1016/j.toxicon.2014.08.067.
  23. Amanita Muscaria – Legal Status. ICEERS URL: https://www.psycheplants.org/index.php/home2/amanita-muscaria-2/ (Дата обращения: 20.05.2024).
  24. Xu X.M., Zhang J.S., Huang B.F. et al. Determination of ibotenic acid and muscimol in plasma by liquid chromatography-triple quadrupole mass spectrometry with bimolecular dansylation. J Chromatogr B Analyt Technol Biomed Life Sci. 2020; 1146: 122128. doi: 10.1016/j.jchromb.2020.122128.
  25. Ramawad H.A., Paridari P., Jabermoradi S. et al. Muscimol as a treatment for nerve injury-related neuropathic pain: a systematic review and meta-analysis of preclinical studies. Korean J Pain. 2023; 36(4): 425–440. doi: 10.3344/kjp.23161.

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Share of acute mushroom poisonings in 2022–2023 years

下载 (226KB)
3. Fig. 2. Main toxins of A. muscaria и A. pantherina [8]

下载 (95KB)

版权所有 © Russkiy Vrach Publishing House, 2025